Flagship VentureLabs launches Seres Health

Friday, November 22, 2013

Flagship VentureLabs has launched Seres Health after two years of development in stealth mode and $10.5 million in Series A financing during that period from Flagship Ventures and other investors. Seres Health is a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on novel scientific findings related to the human microbiome. Seres has developed a unique understanding of the functional nature of the human microbiome and has used this knowledge to pioneer Ecobiotic therapeutics, the first class of agents that addresses the ecological nature of the microbiome. 

[Read More]

Bristol Myers enters clinical collaboration with Tibotec

Friday, December 2, 2011

Bristol-Myers Squibb has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals, one of the Janssen Pharmaceutical companies, to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals’ investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).

[Read More]

EMA recommends INCIVO for hepatitis C virus

Friday, July 29, 2011

Tibotec Virco-Virology BVBA, part of Janssen Pharmaceutical, reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of INCIVO (telaprevir), a direct acting antiviral (DAA) for the treatment of chronic genotype-1 hepatitis C virus (HCV), in combination with pegylated-interferon and ribavirin, the previously accepted standard of care.

[Read More]

Tibotec launches two phase III trials of TMC435

Monday, March 7, 2011

Tibotec Pharmaceuticals is recruiting patients for two global, phase III, double-blind, randomized trials to examine TMC435, its investigational hepatitis C protease inhibitor, in treatment-naive adults with chronic genotype 1 hepatitis C virus (HCV). A third global phase III trial is being conducted in genotype 1 HCV patients who have experienced a viral relapse after prior interferon-based treatment.

[Read More]